Global Health Ltd

Q3 FY24 Earnings Call Analysis

Healthcare Services

Full Stock Analysis
fundraise: No informationcapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
💰

fundraise

Any current/future new fundraising through debt or equity?

- No explicit mention of current or future fundraising through debt or equity in the transcript. - The focus is on ongoing and planned capex for various projects (New facilities in Pitampura, Mumbai, Medical School, Guest House) to be funded over the next three to four years. - Mention of capital inflow in the healthcare industry post-COVID and increased interest from the financial community in building hospitals, but no direct statement about Medanta raising funds. - The company emphasizes sustainable and ethical growth with a long-term view, not radical or short-term capital raising. - CFO Yogesh Kumar Gupta mentions capex plans but does not detail any planned fundraising. - Overall, the discussion centers more around strategic investments and capex management rather than immediate fundraising plans.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- INR 300 crores budgeted for medical school build-out (4-5 lakh sq ft) on 25 acres hospital campus; timeline 3-4 years. - Ongoing Pitampura project (Delhi) with DLF partnership; delayed due to pollution clearances but fully on track. - Indore project currently delayed and stuck in litigation; exploring alternative expansion options. - South Delhi project delayed due to compliance and approval issues. - Mumbai land acquisition completed; part of INR 370 crores capex in H1 FY25. - Total capex guidance: ~INR 470 crores on existing units and INR 500 crores for Noida project over next 3-4 years. - Major medical equipment purchases aligned with hospital development phases. - Focus on expanding capacity (e.g., 118 beds added in Q2 FY25 at Lucknow and Patna). - Commitment to sustainable, ethical growth and strengthening existing facilities alongside new expansions.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- The company expects continued robust volume-driven growth, supported by increased bed capacity and expanded clinical capabilities, especially in developing hospitals like Lucknow and Patna. - Expansion includes capacity addition: 280 beds added in H1 FY25 (150 in Lucknow, 84 in Patna, 50 in Gurugram), with focus on ramping up occupancy. - Introduction of advanced technology, e.g., Da Vinci Xi Surgical Robot, aims to improve patient outcomes and attract more patients. - Matured hospitals show steady revenue growth: 13.5% YoY in Q2 FY25; developing hospitals growing at 4.2% YoY. - International patient revenue is currently around 6%, expected to grow as new NCR facilities come online, though subject to geopolitical risks. - Focus remains on sustainable, ethical growth by strengthening existing services and expanding reach into new areas. - Pipeline projects including new facilities in Pitampura, Mumbai, and Noida expected to contribute incrementally over 3-4 years.
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Strong growth momentum was seen across network hospitals with highest ever quarterly revenue and EBITDA. - Matured hospitals showed 13.5% YoY revenue growth; developing hospitals grew 4.2% YoY. - EBITDA margins improved sequentially to around 25.3%-29.9% across different units. - Expansion includes adding ~280 beds in H1 FY25 and investments in advanced technology like Da Vinci Xi Surgical Robot. - Focus on ramping up occupancy in new beds and increasing clinical capabilities. - Conservative tariff increases to maintain reasonable pricing, supporting steady margin improvement. - Ongoing investments in new facilities (e.g., Pitampura project) and strengthening existing hospital capacities expected to support medium-term growth over next 3-5 years. - Emphasis on gradual, sustainable margin improvement through volume growth, operational efficiencies, and innovation. - Net cash surplus of INR 7,186 million supports capex and expansion plans. - Overall outlook: optimistic with steady EPS and profit growth expected as hospitals mature and occupancy increases.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- The transcript does not explicitly mention a current or expected order book or pending orders. - Capex plans are detailed: INR 470 crores for existing units and INR 500 crores for Noida between Q4 FY25 and Q1 FY26. - Projects in South Delhi and Indore are delayed with uncertain timelines. - Other projects like Mumbai, Pitampura, Medical School, and Guest House are expected to be completed over the next 3-4 years. - The DLF project in Delhi is fully on track but delayed due to pollution control clearances. - Indore has legal issues with landlords; alternative expansion ideas are being explored. - Overall, capex and project completion timelines provide a framework of upcoming commitments rather than a formal order book.